Medical Portal. Disease, Symptoms, Treatment
Home ยป Interactive ยป Nimenrix, comb

Nimenrix, comb


Producer: Pfizer

contains

Nimenrix is ??a vaccine against meningitis.

Active substances

Meningococcal polysaccharide group W135

Meningococcal polysaccharide group Y

Meningococcal polysaccharide group A

Meningococcal polysaccharide group C


Application

Nimenrix is ??used for protection against:

  • Meningitis due to meningococcal bacteria (types A, C, W135 and Y).

Dosage

Available as powder for solution for injection, which is administered in a muscle after dissolution.

Adults and children over 1 year

  • Usually 1 dose a 0.5 ml.
  • Possibly. additional dose.

Children 6-12 weeks

  • Usually 1 dose a 0.5 ml from the 6-week age.
  • An additional dose of 0.5 ml after 2 months and 12 months of age.

possible side effects

Very common (over 10%)

Fever, Impaired appetite, Reaction and discomfort at the injection site *, Fatigue

Drowsiness, Headache, Irritability

Common (1-10%)

Diarrhea, Nausea, Vomiting

Uncommon (0.1-1%)

Pain in the legs and legs

Impaired sensation, dizziness

* Rarely see swelling and redness in a large area, sometimes extensive adjacent joints or the entire arm / leg in which the vaccine is injected.


Should not be used

Nimenrix should not be used in:

  • Allergies for the ingredients
  • Vaccination should be postponed in case of febrile illness.

Pregnancy

Use only under certain conditions.

There is limited experience with the use of Nimenrix in pregnant women. Vaccination should only be done in special cases by agreement with the doctor.


breastfeeding

Can be used if necessary.

Traffic

No warning.

Blood donor

Special quarantine rules for vaccines.

effect

Does the body form antibodies to certain meningococcal bacteria types (types A, C, W135 and Y).


Pharmaceutical forms

Powder and solvent for solution for injection. 1 dose (0.5 ml) contains:

  • 5 microgram meningococcal polysaccharide group A
  • 5 microgram meningococcal polysaccharide group C
  • 5 microgram meningococcal polysaccharide group W135
  • 5 microgram meningococcal polysaccharide group Y.

Special warnings

  • The vaccine does not protect against type B meningococci which causes approximately 70% of meningococcal meningitis in Denmark.
  • The protection against all meningococcal types contained in the vaccine may in some cases be insufficient.
  • The protection may be insufficient in people with impaired immune system.
  • The vaccine should be used with caution to persons with changes in the blood's ability to solidify.

Using other medicines

It is important to inform your doctor about all the medicines you are taking.
  • Nimenrix should as far as possible be given simultaneously with or at least 1 month before other tetanus toxoid vaccines, such as found in vaccines against tetanus.

Grants, delivery, packages and prices

subsidiesextraditionDispensing form and strengthPackingPrice in kr.
May only be delivered once after the same recipe, unless the delivery takes place in several smaller portions at a timepowder and solvent for solution for injection, opl.5 + 5 + 5 + 5 micrograms1 dose370,40



Nimenrix, comb

FAQ - 💬

❓ How do you administer nimenrix?

👉 Nimenrix will be given to you by a doctor or nurse. Nimenrix is always injected into a muscle, usually in the upper arm or thigh. Infants from 6 weeks to less than 6 months of age Two injections given 2 months apart at e.g. 2 and 4 months of age (the first injection may be given from the age of 6 weeks).

❓ What is nimenrix used for?

👉 Nimenrix is a conjugate vaccine that helps to provide protection against invasive disease caused by the bacteria Neisseria meningitidis types A, C, W-135 and Y.

❓ What type of vaccine is nimenrix?

👉 Nimenrix is a meningococcal conjugate vaccine to protect against meningococcal groups A, C, W and Y. In New Zealand, Nimenrix is only available as a purchased vaccine for individuals from 6 weeks of age through your family doctor.

❓ What is the difference between nimenrix and Menactra?

👉 Nimenrix and Menveo provide a slightly better immune response compared with Menactra, and a slower decline in protection over time. However, if Menveo and Nimenrix are unavailable, Menactra should be given as it also provides effective protection.

❓ When should nimenrix be given?

👉 Your baby will receive one dose given from 6 months of age. A booster dose is recommended at 12 months of age, with an interval of at least 2 months after the initial dose. Children from 12 months of age and adults: Most people will be given one NIMENRIX injection.

❓ How many doses of nimenrix are needed?

👉 Infants from 6 months of age, children, adolescents and adults: a single 0.5 mL dose should be administered. An additional primary dose of Nimenrix may be considered appropriate for some individuals (see section 4.4).

❓ How effective is nimenrix?

👉 Nimenrix was compared with several other similar vaccines against N. meningitidis. Results showed that a single injection of Nimenrix was as effective as the other vaccines in stimulating an immune response against all four types of N. meningitidis polysaccharides.

❓ At what age is nimenrix given?

👉 Nimenrix is a vaccine used to protect adults, adolescents and children from the age of 6 weeks against invasive meningococcal disease caused by four groups of the bacterium Neisseria meningitidis (group A, C, W-135, and Y).

❓ How long does nimenrix immunity last?

👉 Long-term antibody persistence data following vaccination with Nimenrix are available up to 10 years after vaccination (see sections 4.4 and 5.1).

❓ How long does meningococcal vaccine last?

👉 For patients who received their most recent dose at age 7 years or older, administer the booster dose 5 years later. Administer boosters every 5 years thereafter throughout life as long as the person remains at increased risk for meningococcal disease.

❓ Does nimenrix prevent meningitis?

👉 Nimenrix is a vaccine used to protect adults, adolescents and children from the age of 6 weeks against invasive meningococcal disease caused by four groups of the bacterium Neisseria meningitidis (group A, C, W-135, and Y).

👉 Nimenrix is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal disease caused by Neisseria meningitidis groups A, C, W-135, and Y. Nimenrix should be used in accordance with available official recommendations.

👉 Details for Nimenrix vaccine and its components. Registered for use in people aged โ‰ฅ6 weeks. MenACWY-TT โ€” quadrivalent meningococcal (serogroups A, C, W, Y)โ€“tetanus toxoid conjugate vaccine

👉 4. Clinical particulars Nimenrix is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal disease caused by Neisseria meningitidis groups A, C, W-135, and Y. Nimenrix should be used in accordance with available official recommendations.

👉 Nimenrix contains small amounts of capsular polysaccharides (sugars from the outer coat) extracted from the four groups of the N. meningitidis bacterium: A, C, W135 and Y.


If You Liked Our Article And You, Have Something To Add, Share Your Thoughts. It Is Very Important To Know Your Opinion!

Add A Comment